AbbVie Files DEF 14A for May 8, 2026 Annual Meeting

Def 14a - Abbvie Inc. (0001551152) (Filer) Filing Summary
FieldDetail
CompanyDef 14a - Abbvie Inc. (0001551152) (Filer)
Filed DateMar 23, 2026
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$85 billion, $61.2B, $56.6B, $19.0B, $13.8B
Sentimentneutral

Complexity: moderate

Sentiment: neutral

Topics: proxy-statement, annual-meeting, corporate-governance

TL;DR

**AbbVie's proxy filing sets the stage for key shareholder votes on May 8, 2026, impacting leadership and strategy.**

AI Summary

AbbVie Inc. filed a DEF 14A proxy statement on March 23, 2026, for its upcoming annual meeting scheduled for May 8, 2026. This filing, identified by SEC Accession No. 0001104659-26-033387, contains crucial information for shareholders, including proposals for director elections, executive compensation, and other corporate governance matters. Investors should review this document to understand the company's strategic direction and how their votes can influence AbbVie's future performance and their investment's value.

Why It Matters

This filing outlines the agenda for AbbVie's annual shareholder meeting, where key decisions affecting the company's leadership and policies will be made. These decisions directly impact the company's governance, executive incentives, and ultimately, shareholder returns.

Risk Assessment

Risk Level: low — This is a routine proxy filing for an annual meeting, which is standard corporate governance and does not inherently present high risk.

Analyst Insight

Investors should carefully review the full DEF 14A document to understand the specific proposals and recommendations from AbbVie's board before the May 8, 2026 annual meeting, as these votes can influence future company direction and shareholder value.

Key Numbers

  • 2026-03-23 — Filing Date (Date the DEF 14A was filed with the SEC)
  • 2026-05-08 — Annual Meeting Date (Date of the shareholder meeting this proxy statement pertains to)
  • 3133527 — Size of DEF 14A document (Indicates the length and detail of the primary proxy statement document)
  • 49 — Number of Documents (Total number of documents included in the filing)

Key Players & Entities

  • AbbVie Inc. (company) — Filer of the DEF 14A
  • 0001551152 (company) — Filer CIK for AbbVie Inc.
  • 0001104659-26-033387 (dollar_amount) — SEC Accession No. for the filing
  • 2026-03-23 (date) — Filing Date
  • 2026-05-08 (date) — Period of Report / Annual Meeting Date

Forward-Looking Statements

  • Shareholders will vote on the election of directors and executive compensation at the May 8, 2026 annual meeting. (AbbVie Inc.) — high confidence, target: 2026-05-08

FAQ

What is the purpose of the DEF 14A filing by AbbVie Inc.?

The DEF 14A filing by AbbVie Inc. (SEC Accession No. 0001104659-26-033387) is an 'Other definitive proxy statement' filed on March 23, 2026, to provide shareholders with information ahead of their annual meeting scheduled for May 8, 2026. It details proposals for shareholder votes, such as director elections and executive compensation.

When is AbbVie Inc.'s annual meeting, according to this filing?

According to the DEF 14A filing, the Period of Report, which typically indicates the date of the annual meeting, is May 8, 2026.

What is the SEC Accession Number for this specific AbbVie Inc. filing?

The SEC Accession No. for this DEF 14A filing by AbbVie Inc. is 0001104659-26-033387.

How many documents are included in this DEF 14A filing?

The filing indicates that there are 49 documents included in this DEF 14A submission.

What is the size of the main DEF 14A document within this filing?

The main DEF 14A document, identified as 'abbv-20260508xdef14a.htm', has a size of 3,133,527 bytes.

Filing Stats: 4,400 words · 18 min read · ~15 pages · Grade level 14.6 · Accepted 2026-03-23 16:59:27

Key Financial Figures

  • $85 billion — ince our inception, we've invested over $85 billion to research, develop, and discover new
  • $61.2B — rm Net Revenues Operating Cash Flow $61.2BN $56.6BN $19.0BN +8.5% operationa
  • $56.6B — enues Operating Cash Flow $61.2BN $56.6BN $19.0BN +8.5% operational growth c
  • $19.0B — erating Cash Flow $61.2BN $56.6BN $19.0BN +8.5% operational growth compared to
  • $13.8B — nvestment Development Pipeline 12 $13.8BN ~90 assets with 2025 net revenues
  • $1.0B — ~90 assets with 2025 net revenues > $1.0BN a substantial increase compared to 20
  • $61.2 b — ional execution Total net revenues of $61.2 billion, driven by strong performance fro
  • $56.6 b — e drove Growth Platform net revenues of $56.6 billion, an increase of 19.6% compared to
  • $2.36 — 0% for Rinvoq. Reported diluted EPS of $2.36 on a GAAP basis and adjusted diluted EP
  • $10.00 — GAAP basis and adjusted diluted EPS of $10.00. See Appendix B for the reconciliation.
  • $19.0 billion — tion. Generated operating cash flow of $19.0 billion. Advancing new medicines and strength
  • $309B — Dividend Total Stockholder Return +$309BN +204% +485% 10-year increase, ad
  • $1.73 — ignificant stockholder value raised to $1.73 per share from $0.57 per share over the
  • $0.57 — r value raised to $1.73 per share from $0.57 per share over the last decade over th

Filing Documents

Executive Compensation Highlights

Executive Compensation Highlights 9 INFORMATION CONCERNING DIRECTOR NOMINEES 10 THE BOARD OF DIRECTORS AND ITS COMMITTEES 18 COMMUNICATING WITH THE BOARD OF DIRECTORS 25 DIRECTOR COMPENSATION 26 SECURITIES OWNERSHIP 29

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 31 Compensation Discussion and Analysis 31 Compensation Committee Report 48 Compensation Risk Assessment 48 Summary Compensation Table 50 2025 Grants of Plan-Based Awards 53 2025 Outstanding Equity Awards at Fiscal Year End 55 2025 Option Exercises and Stock Vested 58 Potential Payments upon Termination or Change in Control 67 RATIFICATION OF ERNST & YOUNG LLP AS ABBVIE'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 70 AUDIT INFORMATION 71 Audit Fees and Non-Audit Fees 71 Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of the Independent Registered Public Accounting Firm 71 Audit Committee Report 72 SAY ON PAY—ADVISORY VOTE ON THE APPROVAL OF EXECUTIVE COMPENSATION 73 MANAGEMENT PROPOSAL TO ELIMINATE SUPERMAJORITY VOTING 74 STOCKHOLDER PROPOSAL 76 Stockholder Proposal on Independent Board Chair 76 ADDITIONAL INFORMATION 79 INFORMATION ABOUT THE ANNUAL MEETING 83 Who Can Vote 83 Notice and Access 83 Voting by Proxy 83 Revoking a Proxy 83 Discretionary Voting Authority 83 Quorum 84 Votes Required for Each Item 84 Inspectors of Election 84 Cost of Soliciting Proxies 85 AbbVie Savings Plan 85 f Table of Contents PROXY SUMMARY About the Meeting This proxy statement and the accompanying proxy are being made available to stockholders on or about March 23, 2026. The accompanying proxy is solicited on behalf of the Board of Directors for use at the Annual Meeting of Stockholders. This summary highlights selected information in the proxy statement. Please review the entire proxy statement and the AbbVie 2025 Annual Report before voting. The voting items expected to be proposed at the meeting are listed below along with the Board's voting recommendations. 2026 Annual Meeting of Stockholders Information Date and Time: Friday, May 8, 2026 at 9:00 a.m. CT Place: Via live webcast online at www.virtualshareholdermee

Executive Compensation Highlights

Executive Compensation Highlights The compensation committee has designed and implemented an executive compensation program in which a substantial majority of named executive officer (NEO) compensation at AbbVie is performance-based. The goals of our compensation program are to: 1 Align executive interests with the drivers of stockholder returns and profitable growth 2 Support achievement of the company's primary business goals to have a remarkable impact on patients' lives 3 Attract and retain world-class executives whose talents and contributions sustain the growth in long-term stockholder value When determining NEO compensation, the committee first considers the median of the competitive marketplace (as derived primarily from the Health Care Peer Group approved by the committee) as an initial benchmark for assessing compensation. The committee then takes into account the company's overall performance against the financial, operating and strategic objectives that were established at the start of the performance period. Finally, specific pay determinations are made for each NEO based on individual performance against goals and contributions to the short- and long-term performance of the company. Key components and design of our executive compensation program: Three primary components make up AbbVie's executive pay program: base salary, short-term incentives, and long-term incentives. The structure of each component is tailored to serve a specific function and purpose. The following is a summary of the key components of our compensation program. Element Type Primary Objective Key Characteristics Base Salary Fixed Attract & retain top talent Individual salaries are established relative to market median based on each NEO's individual performance, skills, experience, and internal equity, as well as the company's annual operating budget Short-Term Incentives At-Risk Encourage achievement of company's primary business goals Plan util

View Full Filing

View this filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.